









Markets
/
Stocks
/
nasdaq-brtx
/

BioRestorative Therapies Inc

BRTX

1.040USD

+0.020+1.96%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.30MMarket Cap

LossP/E TTM



BioRestorative Therapies Inc

1.040

+0.020+1.96%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioRestorative Therapies Inc

Currency: USD Updated: 2026-02-06

Key Insights

BioRestorative Therapies Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 167 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioRestorative Therapies Inc's Score

Industry at a Glance

Industry Ranking

167 / 392

Overall Ranking

318 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

BioRestorative Therapies Inc Highlights

StrengthsRisks

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 234.72% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 401.00K.

Fairly Valued

The company’s latest PE is -0.71, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 88.78K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.000

Target Price

+1162.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioRestorative Therapies Inc is 5.43, ranking 367 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.80K, representing a year-over-year decrease of 94.95%, while its net profit experienced a year-over-year decrease of 178.38%.

Score

Industry at a Glance

Previous score

5.43

Change



Financials

4.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.94

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioRestorative Therapies Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioRestorative Therapies Inc is 7.70, ranking 90 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.71, which is -3922.40% below the recent high of 27.27 and -256.32% above the recent low of -2.54.

Score

Industry at a Glance

Previous score

7.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 167/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of BioRestorative Therapies Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 18.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.000

Target Price

+1162.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

BioRestorative Therapies Inc

BRTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioRestorative Therapies Inc is 5.59, ranking 309 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.18 and the support level at 0.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.36

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.023

Sell

RSI(14)

37.144

Neutral

STOCH(KDJ)(9,3,3)

14.883

Oversold

ATR(14)

0.066

High Vlolatility

CCI(14)

-132.444

Sell

Williams %R

83.678

Oversold

TRIX(12,20)

-0.258

Sell

StochRSI(14)

23.105

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.068

Sell

MA10

1.098

Sell

MA20

1.127

Sell

MA50

1.127

Sell

MA100

1.296

Sell

MA200

1.470

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BioRestorative Therapies Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.80%, representing a quarter-over-quarter decrease of 13.26%. The largest institutional shareholder is The Vanguard, holding a total of 88.78K shares, representing 1.00% of shares outstanding, with 132.82% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Broadrick (Dale)

923.90K

Hale (Morrison Todd)

685.00K

+6.20%

Auctus Fund Management, L.L.C.

434.15K

-0.20%

Alstodt (Lance)

187.50K

+9.09%

Silva (Francisco)

179.61K

+6.98%

Citadel Advisors LLC

106.21K

The Vanguard Group, Inc.

Star Investors

88.78K

+198.61%

Geode Capital Management, L.L.C.

55.27K

+1.86%

Wealth Alliance

40.00K

StoneX Group Inc.

37.45K

-0.78%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioRestorative Therapies Inc is 2.08, ranking 255 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.